

[x](#)

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ELEMENTAL I ANALYTICAL	<i>Second</i>	5633	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First</i>	Line 6: Change

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MPURITIES—LITESTING MITS	<i>Supplement to USP35–NF30</i>					<i>Supplement to USP36–NF31</i>	Pd to: Pb
ACETAZOLAMI ASSAY DE FOR INJECTION	<i>USP35–NF30</i>	2063	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 19: Change 25C(A _U /A _S) to: 250C(A _U /A _S)
AZITHROMYCI IM N FOR INJECTION	<i>Second Supplement to of Azithromycin USP35–NF30 N-Oxide, Desosaminylazithromycin, and N-Demethylazithromycin</i>	5910	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 5 of Analysis: Change Result = (r _U /r _S) × (C _S /C _U) × P × F × 100 to: Result = (r _U /r _S) × (C _S /C _U) × P × 100
FLUTICASONE IM PROPIONATE PURITIES/Organic Impurities	<i>USP35–NF30</i>	3261	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 1 of the Sample solution: Change 2.0 mg/mL to: 0.2 mg/mL
NAFTIFINE HYDROCHLORIDE GEL	<i>Content of alcohol</i>	<i>USP35–NF30</i>	3983	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i> Line 4 of Procedure: Change Calculate the quantity, in mg,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RIBAVIRIN TABLETS	ASSAY/ <i>Procedure</i>	USP35–NF30	4544	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	of C ₂ H ₅ OH in the portion of Gel taken by the formula: to: Calculate the percentage of C ₂ H ₅ OH in the portion of Gel taken by the formula: Line 5 of <i>System suitability</i> in subsection <i>Tailing factor</i> . Change NLT 2.0 to: NMT 2.0
BENTONITE	IDENTIFICATION/A. X-Ray <i>Diffraction</i> <941>	USP35–NF30	1705	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 4 of <i>Acceptance criteria</i> : Change from the pattern of <i>Sample B</i> is 1.492 and 1.504 Å. to: from the pattern of <i>Sample B</i> is between 1.492

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ <i>Dissolution</i> <711>/Test 3	<i>First Supplement to USP35–NF30</i>	5460	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	and 1.504 Å. Line 2 of <i>Analysis</i> : Change <i>Samples: Acid stage standard solution, Buffer stage standard solution, Acid stage sample solutions, and Buffer stage sample solutions</i> to: <i>Samples: Acid stage standard solution, Buffer stage standard solution, and Sample solutions</i>
METHYL ALCOHOL	ASSAY/ <i>Procedure</i>	<i>USP35–NF30</i>	1865	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 9 of <i>System suitability</i> : Change <i>Tailing factor</i> . NLT 1.5 for methyl alcohol, <i>System suitability</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TACROLIMUS CAPSULES	IM PURITIES/ Procedure 2	<i>First Supplement to USP35–NF30</i>	5541	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	<p><i>solution to:</i> <i>Tailing factor:</i> NMT 1.5 for methyl alcohol, <i>System suitability solution</i> Footnote j of <i>Table 5:</i> Change (3S,4R,5S,8S,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-((E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3H</p>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p>-pyri do[2,1-c][1,4]oxaazacycl otricosine-1,7,2 0,21(4<i>H</i>,23<i>H</i>)-tetrone. to: (3<i>S</i>,4<i>R</i>,5<i>S</i>,8<i>R</i> ,9<i>E</i>,12<i>S</i>,14<i>S</i> ,15<i>R</i>,16<i>S</i>,18<i>R</i> ,19<i>R</i>,26<i>aS</i>)-5,6,8, 11,12,1 3,14,15,16,17,1 8,19,24,25,26,2 6a-hexadecahy dro-5,19-dihydr oxy-3-{(<i>E</i>)-2-[(1<i>R</i>,3<i>R</i>,4 <i>R</i>)-4-hydroxy-3-m ethoxycyclohex yl]-1-methylvinyl }-14,16-dimetho xy-4,10,12,18-te tramethyl-15,19 -epoxy-8-propyl -3<i>H</i> -pyri do[2,1-c][1,4]oxaazacycl otricosine-1,7,2</p>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TREHALOSE	ADDITIONAL REQUIREMENTS/USP Reference Standards <11>	USP35–NF30	2007	28-Sep-2012	1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	0, 21(4H,23H)-tetrone. Line 2: Delete USP Glycerin RS	
ELEMENTAL IMPURITIES—PROCEDURES	INTRODUCTORY P/N/Definition	Second Supplement to USP35–NF30	5634	28-Sep-2012	1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Line 2 of Target Elements: Change Pd to: Pb	
AMOXICILLIN TABLETS	PERFORMANCE TESTS	USP35–NF30	2202	28-Sep-2012	1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Line 4 of Analysis: Change Result = $(r_U/r_S) \times (C_S/L) \times (D/V) \times P \times F \times 100$ to: Result = $(r_U/r_S) \times (C_S/L) \times V \times D \times P \times F \times 100$ AND Transpose lines 12 and 13 of the variable definition list to match the order in the equation	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
METFORMIN H YDROCHLORIDE TABLETS	<i>Dissolution</i> <711>/Test 3	USP35–NF30	3830	28-Sep-2012		1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Lines 6 and 7 of Procedure: Change $r_U \times C_S \times 900 \times 100/r_S \times D \times LC$ to: $r_U \times C_S \times 1000 \times 100/r_S \times D \times LC$ AND Line 11 of Procedure: Change 900 is the volume to: 1000 is the volume
POVIDONE	IM PURITIES/ <i>Vinylpyrrolidone</i>	USP35–NF30	4379	28-Sep-2012		1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Line 2 of the Note in <i>Column, Analytical in Chromatographic system</i> : Change 4.0- x 30-mm or a 4.6- x 30-mm guard column to: 4.0-mm x 30-mm or a 4.6-mm x

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ZINC CARBONATE	IM PURITIES/ <i>Iron</i> <241>	USP35–NF30	5068	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	30-mm guard column Line 1 of <i>Sample solution</i> : Change <i>Sample solution</i> : Dissolve 1.0 g in 20 mL of water and 3 mL of hydrochloric acid. to: <i>Test preparation</i> : Dissolve 0.5 g in 20 mL of water and 3 mL of hydrochloric acid.
MICROCRYST ALLINE CELLULOSE	IDENTIFICATIO N/ <i>B. Procedure</i>	USP35–NF30	1746	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	4th formula of <i>Analysis</i> : Change Result = (95) × [?] _c /W _S × [(100 ? %LOD)/100] to: Result = [(95) × [?] _c]/{W _S × [(100 ? %LOD)/100]}

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OMEGA-3-ACID ETHYL ESTERS CAPSULES	SPECIFIC TESTS/ <i>Microbial Enumeration Tests</i> <61> and <i>Tests for Specified Microorganisms</i> <62>	<i>First Supplement to USP35–NF30</i>	5524	28-Sep-2012	ascending	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 2: Change 10 ³ to: 10 ³ cfu/mL AND Line 3: Change 10 ² to: 10 ² cfu/mL AND Line 6: Change <i>Salmonella</i> in 10 g. to: <i>Salmonella</i> species in 10 g.
POLYSORBATE 60	SPECIFIC TESTS/ <i>Acid Value</i>	<i>USP35–NF30</i>	1920	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 1 of <i>Sample</i> : Change 10.0 to: 10.0 g
ELEMENTAL IMPURITIES—LIMITS	DRUG SUBSTANCE AND EXCIPIENTS	<i>Second Supplement to USP35–NF30</i>	5633	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Row 13 of <i>Column 4</i> of <i>Table 2</i> : Change 25 to: 1.0
ADENOSINE	IDENTIFICATION/ <i>Infrared</i>	<i>USP35–NF30</i>	2079	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to</i>	Line 1: Delete NMT

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	<i>Absorption</i> <197M>							USP36–NF31	0.1%
GANCICLOVIR ORAL SUSPENSION	ASSAY	USP35–NF30	3319	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 1 of <i>Internal standard solution:</i> Change 4 mg per mL to: 0.4 mg per mL
POLYVINYL ALCOHOL	<i>Identification test C</i>	USP35–NF30	4351	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 5: Change Add 10 mL of alcohol to the remaining 5 mL of the polyvinyl alcohol solution, and mix to: Add 10 mL of alcohol to the remaining 2 mL of the polyvinyl alcohol solution, and mix.
TYROSINE	IM PURITIES/ <i>Heavy Metals</i> <231>	USP35–NF30	4976	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 1: Change <i>Method I</i> to: <i>Method II</i>
TRIBASIC CALCIUM PHOSPHATE	IDENTIFICATION/ <i>Test A</i>	USP35–NF30	1719	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 1 of the <i>Sample solution:</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ESOMEPRAZO LE MAGNESIUM ELAYED- RELEASE CAPSULES	PERFORMANC E D TESTS/ Dissolution <711>	<i>First Supplement to USP35–NF30</i>	5473	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Change Dissolve 100 mg in 5 mL of diluted nitric acid. to: A solution in a slight excess of nitric acid Line 4 of <i>Medium:</i> Change and adjust with 2 N hydrochloric acid or 2 N sodium, if necessary, to a pH to: and adjust with 2 N hydrochloric acid or 2 N sodium hydroxide, if necessary, to a pH
POLYETHYLE NE OXIDE	IM PUR ITIES/ <i>Organic Impurities/Procedure: Limit of</i>	<i>USP35–NF30</i>	1906	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 2 of <i>System suitability:</i> Change <i>Samples:</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
<i>Free Ethylene Oxide</i>							<i>Standard stock solution and Standard solution C to: Sample: Standard solution C</i>
ELEMENTAL I DRUG IMPURITIES—LISUBSTANCE AND EXCIPIENTS	<i>Second Supplement to USP35–NF30</i>	5633	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Rows 11 and 15 of <i>Column 2</i> of <i>Table 2</i> : Change 100 to: 10 AND Rows 11 and 15 of <i>Column 3</i> of <i>Table 2</i> : Change 10 to: 1.0 AND Row 11 of <i>Column 4</i> of <i>Table 2</i> : Change 1.5 to: 0.15

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ZEIN	IDENTIFICATIO N/C. SDS- Polyacrylamide Gel Electrophoresis	USP35–NF30	2019	28-Sep-2012		1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	AND Row 15 of Column 4 of Table 2: Change 30 to: 3.0 Lines 1 and 2 of the <i>Acceptance criteria</i> : Change Zein has two major bands: the ? band is at 21–25 kDa, and the ? band is at 17–18 kDa. to: Zein has two major bands for ?-zein at 19–26 kDa.
AZITHROMYCI N FOR INJECTION	IM PURITIES/ <i>Limit of Aminoazithro mycin, Formamido Analog, Methylf ormamido Analog, and 3?- De(dimethylami</i>	Second Supplement to USP35–NF30	5910	28-Sep-2012		1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Row 11 of <i>Table 2</i> : Change 3?-Demethyl-3? -N -[(4-methylphen yl)sulfonyl]azithr omycin to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
		<i>no)-3?-oxoazithromycin</i>							3?-N - D eme thyl-3?-N -[(4-methylphenyl)sulfonyl]azithromycin
CHLOROPHYLL LIN COPPER COMPLEX SODIUM METRONIDAZ OLE	SPECIFIC TESTS/ <i>Loss on Drying</i> <231> <i>Related compounds</i>	USP35–NF30	2628	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 1: Change 150° to: 105°
		USP35–NF30	3905	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 19 of <i>Procedure</i> : Change r_i is the peak response for any unspecified degradation product peak in the <i>Test solution</i> to: r_i is the peak response for any single unspecified impurity in the <i>Test solution</i>
PRILOCAINE AND	<i>Assay for epinephrine</i>	USP35–NF30	4411	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to</i>	Line 7 of <i>Procedure</i> :

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EPINEPHRINE INJECTION								USP36–NF31	Change 183.21/333.30 to: 183.20/333.29 AND Line 8 of <i>Procedure:</i> Change 183.21 and 333.30 to: 183.20 and 333.29

Pagination

- [First page « First](#)
- [Previous page ‹ Previous](#)
- ...
- [Page 32](#)
- [Page 33](#)
- [Page 34](#)
- [Page 35](#)
- [Page 36](#)
- [Page 37](#)
- [Page 38](#)
- [Page 39](#)
- [Page 40](#)